Drug intelligence / Profile preview

SNA001

Development stage: Unknown
Lead developer: SmartNuclide
Modality: Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

SNA001 is a novel recombinant human thyroid-stimulating hormone (rhTSH) developed for use in the diagnosis and treatment of differentiated thyroid carcinoma (DTC). It is designed to stimulate iodine-131 uptake and thyroglobulin secretion, facilitating radioiodine ablation and monitoring of DTC without requiring patients to undergo hypothyroidism induced by thyroid hormone withdrawal. Clinical studies have demonstrated that SNA001 is noninferior to traditional thyroid hormone withdrawal protocols for preparing patients for radioactive iodine therapy, with a favorable safety profile and fewer adverse events. The drug is administered via intramuscular injection[4][5][9].

Other names: SNA001 rhTSHSNA-001 rhTSHSNA 001 rhTSH

Targets

TSHR (Thyroid-stimulating hormone receptor)

Beyond the preview

Go deeper on SNA001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNA001.

Explore the full profile